HK Stock Market Move | CSTONE PHARMA-B(02616) rose more than 4%, executive director Yang Jianxin once again increased holdings, accumulating nearly 12.48 million shares purchased.

CSTONE PHARMA-B(02616) rose more than 4%, as of the time of writing, it has increased by 4.24% to 5.66 Hong Kong dollars, with a trading volume of 14.93 million Hong Kong dollars. On the news front, on January 27th, CSTONE Pharma announced that the company's CEO, Chief Research Officer, and Executive Director Dr. Yang Jianxin has informed that he has purchased a total of 976,000 shares in the open market with personal funds from November 2025 to January 2026, with only 428,500 shares purchased on January 22nd and 23rd, 2026. This recent purchase continues Dr. Yang's consistent commitment. Since assuming the role of CEO in August 2022, Dr. Yang has accumulated a total of 12,477,000 shares. Following this share purchase, Dr. Yang holds a total of approximately 4.87% of the company's issued share capital as of the announcement date. Dr. Yang stated that he is confident in the company's long-term investment value and core competitive advantages, and his increased holdings also represent his belief in the company's ability to maintain stable operations and high-quality growth in the future. Dr. Yang does not rule out the possibility of further increasing his holdings in the company at the appropriate time.